Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials
<p><strong>Background:</strong> Use of cell-based medicinal products (CBMPs) represents a state-of-the-art approach for reducing general immunosuppression in organ transplantation. We tested multiple regulatory CBMPs in kidney transplant trials to establish the safety of r...
Main Authors: | Sawitzki, B, Harden, PN, Reinke, P, Roberts, ISD, Hester, J, van der Net, JB, Petchey, W, Issa, F, Morris, PJ, Bushell, A, Friend, P, Wood, K, Geissler, EK, Et al. |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2020
|
Similar Items
-
Regulatory cell therapy in kidney transplantation (The ONE Study): A harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials
by: Sawitzki, B, et al.
Published: (2020) -
Feasibility, long‐term safety and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients
by: Harden, PN, et al.
Published: (2020) -
Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients
by: Brook, MO, et al.
Published: (2022) -
Dampened inflammatory signalling and myeloid-derived suppressor-like cell accumulation reduces circulating monocytic HLA-DR density and may associate with malignancy risk in long-term renal transplant recipients
by: Bottomley, MJ, et al.
Published: (2022) -
CD45RA identifies TSDR demethylated regulatory T cells with a stable phenotype and suppressive cytokine profile
by: Hornero, RA, et al.
Published: (2016)